SCHEMBL336303

SCHEMBL336303

COc1ccc([N+](=O)[O-])c(N)n1

nearest known ligand 0.56

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
TXNRD1 Q16881 18/20 0.56
S1PR4 O95977 2/20 0.52
MAPT P10636 2/20 0.52
S1PR1 P21453 2/20 0.52
MAPK1 P28482 2/20 0.52
NPSR1 Q6W5P4 2/20 0.52
RAB9A P51151 1/20 0.52
GFER P55789 1/20 0.52
PAX8 Q06710 1/20 0.52
JAK2 O60674 1/20 0.51
HSP90AA1 P07900 1/20 0.51
HTT P42858 1/20 0.51
GSR P00390 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31056308 1.00 TXNRD1 (0.56) TXNRD1S1PR4MAPTS1PR1MAPK1
SCHEMBL6027123 0.94 TXNRD1 (0.51) TXNRD1S1PR4MAPTS1PR1MAPK1
SCHEMBL13657691 0.88 TXNRD1 (0.46) TXNRD1S1PR4MAPTS1PR1MAPK1
SCHEMBL2411887 0.82 TDP1 (0.39) TXNRD1S1PR4MAPTS1PR1MAPK1
SCHEMBL2302904 0.81 MAPT (0.53) TXNRD1MAPTMAPK1RAB9AGSR
SCHEMBL1428159 0.80 TXNRD1 (0.58) TXNRD1S1PR4MAPTS1PR1MAPK1
SCHEMBL29830024 0.80 TXNRD1 (0.58) TXNRD1S1PR4MAPTS1PR1MAPK1
SCHEMBL1848090 0.80 TXNRD1 (0.58) TXNRD1S1PR4MAPTS1PR1MAPK1
SCHEMBL10740434 0.80 TXNRD1 (0.58) TXNRD1S1PR4MAPTS1PR1MAPK1
SCHEMBL27175931 0.80 TXNRD1 (0.62) TXNRD1S1PR4MAPTS1PR1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 231 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118994151-A Imidazopyridone compounds binding to sigma-2 receptor, preparation method and application thereof 北京师范大学 2024-11-22 CN claimed
CN-102040607-A Synthetic process of intermediate for producing tenatoprazole TIANJIN SANNONGJIN TECHNOLOGY 2011-05-04 CN claimed
CN-1982311-B Synthesis of 2-hydrophobic-5-methoxy-diazole [4,5-b]-dipyridine WEIZHI FINE CHEMICAL CO LTD TIANJIN 2010-10-13 CN claimed
US-7256295-B2 Process for producing 2,3-diamino-6-methoxypyridine JUBILANT ORGANOSYS LIMITED (IN) 2007-08-14 US claimed
CN-1982311-A Synthesis of 2-hydrophobic-5-methoxy-diazole [4,5-b]-dipyridine WEIZHI PREC CHEMICAL CO LTD TI (CN) 2007-06-20 CN claimed
US-20060080790-A1 Process for producing 2,3-diamino-6-methoxypyridine JUBILANT ORGANOSYS LIMITED (IN) 2006-04-20 US claimed
EP-0199951-B1 PROCESS FOR THE PREPARATION OF 2-AMINO-3-NITRO-6-(4-FLUOROBENZYLAMINO) PYRIDINE AND OF 2-AMINO-3-CARBETHOXYAMINO-6-(4-FLUOROBENZYLAMINO) PYRIDINE ASTA Pharma Aktiengesellschaft (DE) 1991-01-23 EP claimed
US-4785110-A Process for the production of 2-amino-3-nitro-6-(4-fluorobenzylamino)-pyridine DEGUSSA AKTIENGESELLSCHAFT (DE) 1988-11-15 US claimed
EP-0199951-A2 Process for the preparation of 2-amino-3-nitro-6-(4-fluorobenzylamino) pyridine and of 2-amino-3-carbethoxyamino-6-(4-fluorobenzylamino) pyridine ASTA Pharma Aktiengesellschaft (DE) 1986-11-05 EP claimed
WO-2026088070-A1 COMPOUNDS PFIZER INC. (US) 2026-04-30 WO disclosed
EP-4121423-B1 TETRAZOLE DERIVATIVES MERCK PATENT GMBH (DE) 2026-04-29 EP disclosed
EP-4725493-A2 POLYCYCLIC COMPOUNDS FOR INHIBITING RNA HELICASE DHX33 AND USE THEREOF Shenzhen Keye Life Technologies, Co., Ltd. (CN) 2026-04-15 EP disclosed
EP-4121429-B1 CONDENSED PYRIDINE DERIVATIVES SUBSTITUED BY AMIDE FUNCTIONS AS ACSS2 INHIBITORS MERCK PATENT GMBH (DE) 2025-08-13 EP disclosed
CN-115335371-B Tetrazole derivatives 默克专利股份公司 2024-12-27 CN disclosed
EP-0623620-A1 5-HT3 Pyrrolopyrazine derivatives ADIR ET COMPAGNIE (FR) 1994-11-09 EP disclosed
EP-0199951-B1 PROCESS FOR THE PREPARATION OF 2-AMINO-3-NITRO-6-(4-FLUOROBENZYLAMINO) PYRIDINE AND OF 2-AMINO-3-CARBETHOXYAMINO-6-(4-FLUOROBENZYLAMINO) PYRIDINE ASTA Pharma Aktiengesellschaft (DE) 1991-01-23 EP disclosed
US-4785110-A Process for the production of 2-amino-3-nitro-6-(4-fluorobenzylamino)-pyridine DEGUSSA AKTIENGESELLSCHAFT (DE) 1988-11-15 US disclosed
US-4785110-A Process for the production of 2-amino-3-nitro-6-(4-fluorobenzylamino)-pyridine DEGUSSA AKTIENGESELLSCHAFT (DE) 1988-11-15 US disclosed
EP-0199951-A2 Process for the preparation of 2-amino-3-nitro-6-(4-fluorobenzylamino) pyridine and of 2-amino-3-carbethoxyamino-6-(4-fluorobenzylamino) pyridine ASTA Pharma Aktiengesellschaft (DE) 1986-11-05 EP disclosed
EP-0199951-A2 Process for the preparation of 2-amino-3-nitro-6-(4-fluorobenzylamino) pyridine and of 2-amino-3-carbethoxyamino-6-(4-fluorobenzylamino) pyridine ASTA Pharma Aktiengesellschaft (DE) 1986-11-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060080790-A1 Process for producing 2,3-diamino-6-methoxypyridine TET2, QDPR, PNMT TXNRD1 2840/4885S1PR4 880/4885MAPT 1845/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.